Streetbeat News

Products Services

GKOS

Glaukos Corporation (GKOS) has announced that it will become the exclusive sales agent to market, promote, and solicit orders for the Radius XR system.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 11:07 am

TNXP

Tonix Pharmaceuticals has announced an agreement and the initiation of enrollment in a Phase 2 trial with the University of Washington. The trial will study TNX-1900, a potentiated intranasal oxytocin, for the treatment of social anxiety disorder.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 11:06 am

BLRX

BioLineRx has initiated a Phase 2 trial for first-line metastatic pancreatic cancer based on preliminary data from the single-arm pilot phase. The trial includes the investigational candidate Motixafortide.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 11:05 am

BBIO

BridgeBio Pharma has announced results from its Phase 3 ATTRibute-CM study of Acoramidis, showing an 81% on-treatment survival rate compared to 74% on placebo. The study also showed a highly statistically significant improvement in the primary endpoint, a 50% relative risk reduction on frequency of cardiovascular-related hospitalization, and no safety signals of potential clinical concern were identified.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 11:05 am

COYA

Coya Therapeutics has reported additional clinical data from an open-label study evaluating the safety and efficacy of low-dose interleukin 2 (ld IL-2) in patients with Alzheimer's disease. The data shows a significant decrease in biomarker levels associated with neuroinflammation, supporting the initial positive results. The treatment also demonstrated biological activity by restoring peripheral Treg function and numbers and significantly lowering the blood levels of other proinflammatory cytokines and chemokines. An ongoing phase 2 trial is almost fully enrolled and should report top line results in July, 2024.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 11:02 am

BPTH

Bio-Path Holdings, Inc. (BPTH) has completed the first dose cohort of the dose escalation portion of its Phase 1/1b clinical trial of BP1001-A (Liposomal Grb2) in patients with solid tumors.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 11:02 am

RKLB

Rocket Lab USA, Inc. (NASDAQ:RKLB) is set to launch a mix of satellites for NASA and commercial satellite operators in a mission called 'Baby Come Back'. This will be Rocket Lab's seventh Electron launch of 2023 and its second recovery mission this year. The company will also release its Q2 financial results on August 8. RKLB shares are trading higher by 1.90% to $6.44 in the premarket session.

Portfolio Pulse from Nabaparna Bhattacharya

July 17, 2023 | 10:50 am

SPCE

Virgin Galactic Holdings, Inc. (NYSE:SPCE) has announced the crew of its seventh spaceflight and second commercial spaceflight, ‘Galactic 02,' which will fly three private passengers to space. This mission is expected to achieve several historical milestones and further the Company's mission of broadening access to space.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 10:48 am

LEU

TerraPower and Centrus Energy Corp. (NYSE:LEU) have announced a new memorandum of understanding (MOU) to expand their collaboration for establishing commercial-scale, domestic production capabilities for high-assay, low-enriched uranium (HALEU). The HALEU will supply TerraPower's Natrium reactor and energy storage system.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 10:47 am

ARGX

Argenx has reported positive topline data from its adhere study of Vyvgart Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy, leading to a rise in its share price.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 10:22 am